NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions

Breast NeoplasmsProstate NeoplasmsNeoplasms, Squamous CellMelanomaMesotheliomaPancreatic NeoplasmsColorectal NeoplasmsCarcinoma, Renal CellLiver Neoplasms

Interventions

DRUG

PF-06952229

Oral 7 days on / 7 days off - 28 day cycles (Part 1)

DRUG

Enzalutamide

Prostate Cancer (Part 2). 160mg, capsules, orally, daily

Trial Locations (15)

37203

Sarah Cannon Research Institute - Pharmacy, Nashville

Tennessee Oncology, PLLC, Nashville

The Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville

The Sarah Cannon Research Institute, Nashville

73104

OU Medical Center Presbyterian Tower, Oklahoma City

Stephenson Cancer Center, Oklahoma City

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

85258

HonorHealth, Scottsdale

90404

UCLA Dept of Medicine -Hematology/Oncology,Santa Monica, Santa Monica

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

01923

Mass General/ North Shore Center for Outpatient Care, Danvers

02459

Dana-Farber Cancer Institute - Chestnut Hill, Newton